期刊名：Antibodies

期刊主页：https://www.mdpi.com/journal/antibodies

本期编辑荐读为您精选2024年发表于 Antibodies 期刊的十篇高引文章。希望能为相关领域学者提供新的思路和参考，欢迎阅读。

1. Diagnosis and Management of Catastrophic Antiphospholipid Syndrome and the Potential Impact of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria

灾难性抗磷脂综合征的诊断和治疗以及2023年ACR/EULAR抗磷脂综合征分类标准的潜在影响

Lucas Jacobs, Nader Wauters, Yahya Lablad, Johann Morelle and Maxime Taghavi

https://www.mdpi.com/2073-4468/13/1/21

2. Immunogenicity and Loss of Effectiveness of Biologic Therapy for Inflammatory Bowel Disease Patients Due to Anti-Drug Antibody Development

抗药抗体的产生导致炎症性肠病患者生物疗法的免疫原性和疗效丧失

Tsvetelina Velikova, Metodija Sekulovski and Monika Peshevska-Sekulovska

https://www.mdpi.com/2073-4468/13/1/16

3. Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database

PD-1、PD-L1、CTLA-4 和 LAG-3 免疫检查点抑制剂的不良事件：FDA 不良事件数据库分析

Connor Frey and Mahyar Etminan

https://www.mdpi.com/2073-4468/13/3/59

4. Antiphospholipid Antibodies Associated with Native Arteriovenous Fistula Complications in Hemodialysis Patients: A Comprehensive Review of the Literature

抗磷脂抗体与血液透析患者自体动静脉瘘并发症的关系：文献综述

Maxime Taghavi, Abla Jabrane, Lucas Jacobs, Maria Do Carmo Filomena Mesquita, Anne Demulder and Joëlle Nortier

https://www.mdpi.com/2073-4468/13/1/1

5. Myelin Oligodendrocyte Glycoprotein-Antibody Associated Disease: An Updated Review of the Clinical Spectrum, Pathogenetic Mechanisms and Therapeutic Management

髓鞘少突胶质细胞糖蛋白抗体相关疾病：临床谱、发病机制和治疗管理的最新综述

Panagiotis Gklinos and Ruth Dobson

https://www.mdpi.com/2073-4468/13/2/43

6. A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments

皮肤T细胞淋巴瘤CCR4疗法现状叙述性回顾：重点关注Mogamulizumab及未来疗法

Corrado Zengarini, Alba Guglielmo, Martina Mussi, Giovanna Motta, Claudio Agostinelli, Elena Sabattini, Bianca Maria Piraccini and Alessandro Pileri

https://www.mdpi.com/2073-4468/13/2/32

7. Therapeutic Advances in Psoriasis: From Biologics to Emerging Oral Small Molecules

银屑病治疗进展：从生物制剂到新兴口服小分子药物

Francesco Ferrara, Chiara Verduci, Emanuela Laconi, Andrea Mangione, Chiara Dondi, Marta Del Vecchio, Veronica Carlevatti, Andrea Zovi, Maurizio Capuozzo and Roberto Langella

https://www.mdpi.com/2073-4468/13/3/76

8. Unveiling GFAP Astrocytopathy: Insights from Case Studies and a Comprehensive Review of the Literature

揭秘GFAP星形胶质细胞病：案例研究的见解和全面的文献综述

Panagiotis Gklinos, Fotios Athanasopoulos, Vagia Giatrakou, Nikolaos-Achilleas Arkoudis, Dorothea Pournara, Eirini Giagkou, Argyro Tountopoulou, Sofia Vassilopoulou and Dimos-Dimitrios Mitsikostas

https://www.mdpi.com/2073-4468/13/4/79

9. A Comparison of Natural and Therapeutic Anti-IgE Antibodies

天然和治疗性抗IgE抗体的比较

Monique Vogel and Paul Engeroff

https://www.mdpi.com/2073-4468/13/3/58

10. TLR2 and TLR9 Blockade Using Specific Intrabodies Inhibits Inflammation-Mediated Pancreatic Cancer Cell Growth

使用特定胞内抗体阻断TLR2和TLR9可抑制炎症介导的胰腺癌细胞生长

Amrendra K. Ajay, Martin Gasser, Li-Li Hsiao, Thomas Böldicke and Ana Maria Waaga-Gasser

https://www.mdpi.com/2073-4468/13/1/11